76 / 1266
Difficult to draw conclusions from
small trials
OS no different in pooled analysis
–
possible improvement in FIS and
reduction of neurological deaths
Pts likely to benefit: young age, good
neurological function and controlled
primary disease
Decision should be made in MDT
Brain metastases